Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 5/20 | 0.34 |
| ▸ | WDR77 | Q9BQA1 | 5/20 | 0.34 |
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19344253 | 0.90 | PRMT5 (0.35) | PRMT5WDR77NAMPTALDH1A1CYP2D6 | |
| SCHEMBL19343846 | 0.87 | PRMT5 (0.35) | PRMT5WDR77NAMPTCYP11B2 | |
| SCHEMBL19344045 | 0.85 | PRMT5 (0.36) | PRMT5WDR77NAMPTMEN1KMT2A | |
| SCHEMBL19343848 | 0.85 | EIF2AK4 (0.37) | PRMT5WDR77NAMPTADORA1 | |
| SCHEMBL19344265 | 0.82 | PRMT5 (0.43) | PRMT5WDR77 | |
| SCHEMBL23584732 | 0.81 | CYP2D6 (0.37) | NAMPTALDH1A1CYP2D6CYP11B2GPR119 | |
| SCHEMBL19343828 | 0.79 | PRMT5 (0.43) | PRMT5WDR77 | |
| SCHEMBL19344420 | 0.79 | NAMPT (0.36) | PRMT5WDR77NAMPT | |
| SCHEMBL23584593 | 0.79 | NAMPT (0.37) | NAMPTALDH1A1CYP2D6CYP11B2GPR119 | |
| SCHEMBL19344422 | 0.78 | PRMT5 (0.39) | PRMT5WDR77NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289539-A1 | NOVEL SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | PRMT5 1/4885WDR77 133/4885NAMPT 172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.